![](/img/cover-not-exists.png)
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer
Gradishar, William J., Kaklamani, Virginia, Sahoo, Tarini P., Lokanatha, Dasappa, Raina, Vinod, Bondarde, Shailesh, Jain, Minish, Ro, Sunhee Kwon, Lokker, Nathalie A., Schwartzberg, LeeVolume:
49
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2012.08.005
Date:
January, 2013
File:
PDF, 820 KB
english, 2013